TRADING UPDATES: IAG launches new buyback; Forgent settles legal case
15th May 2026 18:23
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday. Read More
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday. Read More
ValiRx PLC - London-based life science company - Establishes wholly owned subsidiary ValiRx Animal Health Ltd to develop and commercialise its oncology assets in the veterinary market. The subsidiary will use preclinical work from ValiRx human programmes to pursue comparative oncology opportunities. "There is a strong scientific rationale, as well as market opportunities, for this ethical approach and several examples of companies that have followed this route," says Chief Executive Officer Mark Eccleston, who adds that the three key areas of focus will be Osteosarcoma, Lymphoma and Hemangiosarcoma. ValiRx said specialist veterinary venture capitalist funds have been identified and approached with the intention that the subsidiary will be independently funded. The global veterinary oncology market was valued at USD1.58 billion in 2024 and is projected to reach USD4.86 billion by 2034, representing a compound annual growth rate of 12%. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More
(Alliance News) - Stock prices in London opened lower on Thursday, as the FTSE 100 retreated from a record high in the wake of a "hawkish" cut by the Federal Reserve. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - ValiRx PLC on Monday said it has received a notice of allowance from the European Patent Office for "nanoparticle for anti-cancer peptides and uses thereof", a key patent application for majority-owned subsidiary Cytolytix Ltd. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday. Read More
(Alliance News) - ValiRx PLC on Tuesday announced its establishment of a new wholly-owned subsidiary, and plans to file new patents for Val201. Read More
(Alliance News) - ValiRx PLC on Monday said subsidiary Inaphaea BioLabs has agreed an exclusive licensing deal with Dominion Biotech Ltd for Inaphaea's PredictRx platform. Read More
(Corrects the name of the AJ Bell analyst quoted.) Read More
(Alliance News) - Stock prices in London were higher at midday on Friday, amid a slight lull in tensions over the Israel-Iran conflict after US President Donald Trump gave himself two weeks to decide whether to join Israel's strikes on Iran. Read More
(Alliance News) - ValiRx PLC shares surged on Friday as it said Ambrose Healthcare Ltd has exercised its option to licence its VAL401 asset for GBP16 million plus royalties. Read More
(Alliance News) - ValiRx PLC on Tuesday said subsidiary Cytolytix Ltd has entered an evaluation and material transfer agreement with California-based biotechnology firm Omios Biologics. Read More
ValiRx PLC - Essex-based life sciences company focusing on early-stage cancer therapeutics and women's health - signs an extension to the evaluation and commercial use agreement with UK based Dominion Biotech Ltd announced on April 30. Under the extension, Inaphaea will share access to results from a proprietary screen of around 3000 Food & Drug Administration approved drugs generated in a panel of patient derived cells. The drugs are approved for non-cancer applications and Dominion will mine the data for potential cancer applications, carrying out routine analysis to validate the most promising candidates at its own expense; the parties will agree and share any additional in-depth studies if required. The results of the analysis will be jointly owned, and both parties will share equally all costs associated with filing, prosecution and maintenance of any arising patents for any repurposed drugs. The parties will work together to commercialise any new assets either to the owner of the original drug compounds or alternative companies interested in the repurposed assets. All revenue generated will be equally shared after costs. Read More